The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Editas Medicine's share price is $5.265.
Editas Medicine's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.98. Hence, Editas Medicine's PS Ratio for today is 5.36.
Good Sign:
Editas Medicine Inc stock PS Ratio (=5.22) is close to 10-year low of 5.22
The historical rank and industry rank for Editas Medicine's PS Ratio or its related term are showing as below:
EDIT'
s PS Ratio Range Over the Past 10 Years
Min: 5.42 Med: 48.61 Max: 467.89
Current: 5.5
During the past 11 years, Editas Medicine's highest PS Ratio was 467.89. The lowest was 5.42. And the median was 48.61.
EDIT's PS Ratio is ranked better than 65.16% of 993
companies
in the Biotechnology industry
Industry Median: 9.09
vs EDIT: 5.50
Editas Medicine Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Editas Medicine was 258.20% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -12.80% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -1.20% per year.
During the past 11 years, Editas Medicine's highest 3-Year average Revenue per Share Growth Rate was 145.20% per year. The lowest was -17.70% per year. And the median was 9.25% per year.
Back to Basics: PS Ratio
Editas Medicine PS Ratio Historical Data
The historical data trend for Editas Medicine's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Editas Medicine's PS Ratio
For the Biotechnology subindustry, Editas Medicine's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Editas Medicine's PS Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Editas Medicine's PS Ratio distribution charts can be found below:
* The bar in red indicates where Editas Medicine's PS Ratio falls into.
Editas Medicine PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Editas Medicine's Share Price of today is $5.265. Editas Medicine's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.98.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Editas Medicine PS Ratio Related Terms
Thank you for viewing the detailed overview of Editas Medicine's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Editas Medicine (Editas Medicine) Business Description
Editas Medicine Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
EDIT has been successfully added to your 